ClinicalTrials.gg
CompletedNCT01412333Updated Mar 8, 2024Results posted

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

A Phase 3 interventional study of Interferon beta-1a and Ocrelizumab-matching placebo in Relapsing Multiple Sclerosis, sponsored by Hoffmann-La Roche. Completed at 165 sites in 24 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-03-08.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
835
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.

Enrollment
4th of 27
835 · median 170
Started
2011
with 1 other
Phase 3
13 of 27
2 open now
Registered
2nd of 27
by date
Lead sponsor
13 of 27
Hoffmann-La Roche

Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 4th largest by enrollment, is one of 2 that started in 2011, is one of 13 in phase 3, and was the 2nd registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ocrelizumab in Multiple Sclerosis, or all of them as a file.
02

Study summary

This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis. Participants will be randomized to receive either ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week; or interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria (2010)
  • At least 2 documented clinical attacks within the last 2 years prior to screening or one clinical attack in the years prior to screening (but not within 30 days prior to screening)
  • Neurologic stability for greater than or equal to (>/=) 30 days prior to both screening and baseline
  • Expanded Disability Status Scale (EDSS) score 0 to 5.5 inclusive

Exclusion criteria

Exclusion Criteria:

  • Primary progressive multiple sclerosis
  • Disease duration of more than 10 years in patients with EDSS score less than or equal to (\</=) 2.0 at screening
  • for MRI
  • Known presence of other neurological disorders which may mimic multiple sclerosis
  • Pregnancy or lactation
  • Requirement for chronic treatment with systemic or during the course of the study
  • History of or currently active primary or secondary immunodeficiency
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
  • Active infection, or history of or known presence of recurrent or chronic infection (for example, or C, [HIV], syphilis, tuberculosis)
  • History of progressive multifocal leukoencephalopathy
  • Contraindications to or intolerance of oral or IV corticosteroids
  • Contraindications to Rebif or incompatibility with Rebif use
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
835 participants (actual)

Study arms

  • Active comparator
    Interferon beta-1a 44 mcg SC

    Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).

    Drug: Interferon beta-1a · Drug: Ocrelizumab-matching placebo

  • Experimental
    Ocrelizumab

    Ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.

    Drug: Ocrelizumab · Drug: Interferon beta-1a-matching placebo

Interventions

  • Also known as: Rebif

  • DrugOcrelizumab-matching placebo
  • Also known as: RO4964913

  • DrugInterferon beta-1a-matching placebo
06

What researchers measure

Primary outcomes

  1. Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks In Double Blind Period

    ARR was protocol-defined and calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of exposure to that treatment.

    Time frame: Week 96

Secondary outcomes

  1. Time to Onset of Confirmed Disability Progression (CDP) for at Least 12 Weeks During the Double-Blind Treatment Period

    Disability progression was defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) \>=1.0 point from the baseline EDSS score when the baseline score was less than or equal to (\<=) 5.5 B) \>=0.5 point from the baseline EDSS score when the baseline score was \>5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined. Disability progression was considered confirmed when the increase in the EDSS was confirmed at a regularly scheduled visit at least 12 weeks after the initial documentation of neurological worsening. Participants who had initial disability progression with no confirmatory EDSS assessment and who were on treatment at time of clinical cut-off date were censored at the date of their last EDSS assessment.

    Time frame: Week 104

  2. Number of T1 Gadolinium (Gd)-Enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-Blind Treatment

    The total number of T1 gadolinium-enhancing lesions for all participants in the treatment group was calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96.

    Time frame: Baseline up to week 96

  3. Number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double Blind Treatment

    The total number of new and/or enlarging T2 lesions for all participants in the treatment group was calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96.

    Time frame: Baseline up to week 96

  4. Percentage of Participants With Confirmed Disability Improvement (CDI) for at Least 12 Weeks In Double Blind Period

    Disability improvement was assessed only for the subgroup of participants with a baseline EDSS score of \>= 2.0. It was defined as a reduction in EDSS score of: A) \>=1.0 from the baseline EDSS score when the baseline score was \>=2 and \<=5.5 B) \>= 0.5 when the baseline EDSS score \> 5.5. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined.

    Time frame: Week 96

  5. Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks During the Double-Blind Treatment Period

    Disability progression was defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) \>=1.0 point from the baseline EDSS score when the baseline score was less than or equal to (\<=) 5.5 B) \>=0.5 point from the baseline EDSS score when the baseline score was \>5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined. Disability progression was considered confirmed when the increase in the EDSS was confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. Participants who had initial disability progression with no confirmatory EDSS assessment and who were on treatment at time of clinical cut-off date were censored at the date of their last EDSS assessment.

    Time frame: Week 104

  6. Number of T1 Hypointense Lesions During the Double-Blind Treatment

    The total number of new T1-Hypo-Intense Lesions (Chronic Black Holes) for all participants in the treatment group was calculated as the sum of the individual number of new lesions at Weeks 24, 48, and 96.

    Time frame: Baseline up to week 96

  7. Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score to Week 96 In Double Blind Period

    MSFC score consists of: A) Timed 25-Foot walk; B) 9-Hole Peg Test (9-HPT); and C) Paced Auditory Serial Addition Test (PASAT-3 version). The MSFCS is based on the concept that scores for these three dimensions (arm, leg, and cognitive function) are combined to create a single score (the MSFC) that can be used to detect change over time in a group of participants with MS. Since the three primary measures differ in what they actually measure, a common composite score for the three different measures i.e., Z- score was selected for the purpose. MSFC Score = {Z arm, average + Z leg, average + Z cognitive} / 3.0. The results from each of these three tests are transformed into Z-scores and averaged to yield a composite score for each participant at each time point. A score of +1 indicates that, on average, an individual scored 1 standard deviation (SD) better than the reference population and a score of -1 indicates that an individual scored 1 SD worse than the reference population.

    Time frame: Baseline, Week 96

  8. Percent Change in Brain Volume as Detected by Brain Magnetic Resonance Imaging (MRI) From Week 24 to Week 96 In Double Blind Period

    Brain volume was recorded as an absolute "normalized" value at the baseline visit then recorded at subsequent visits as a percentage change relative to the absolute value at the baseline visit. Therefore, brain volume at Week 24 was calculated as the brain volume at the baseline visit multiplied by 1 + (\[percentage change in brain volume from baseline visit to Week 24\]/100). Estimates are from analysis based on mixed-effect model of repeated measures (MMRM) using unstructured covariance matrix: Percentage Change = Brain Volume at Week 24 + Geographical Region (US vs. ROW) + Baseline EDSS (\< 4.0 vs. \>= 4.0) + Week + Treatment + Treatment\*Week (repeated values over Week) + Brain Volume at Week 24\*Week. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis).

    Time frame: From week 24 up to week 96

  9. Change From Baseline in Short Form Health Survey-36 (SF-36) Physical Component Summary (PCS) Score at Week 96 In Double Blind Period

    The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t- scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.

    Time frame: Baseline, Week 96

  10. Percentage of Participants Who Have No Evidence of Disease Activity (NEDA) up to Week 96 In Double Blind Period

    NEDA was defined only for participants with a baseline EDSS score \>=2.0. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). Participants who completed the 96- week treatment period were considered as having evidence of disease activity if at least one protocol- defined relapse (PDR), a confirmed disability progression (CDP) event or at least one MRI scan showing MRI activity (defined as Gd-enhancing T1 lesions, or new or enlarging T2 lesions) was reported during the 96-week treatment period, otherwise the participant was considered as having NEDA.

    Time frame: Week 96

  11. Number of Participants With Adverse Events (AEs)

    AEs included infusion related reactions (IRRs) and serious MS relapses, but excluded non-serious MS relapses. Serious Adverse Events (SAEs) included serious MS relapses and serious IRRs.

    Time frame: Baseline up to Week 96

  12. Exposure to Ocrelizumab (Area Under the Concentration - Time Curve, AUC) In Double Blind Period

    AUC represents total drug exposure for one dosing interval after the 4th dose.

    Time frame: Pre-infusion at Weeks 1, 24, 48, 72; and 30 minutes post-infusion at Week 72; at any time during Weeks 84 and 96

  13. Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab In Double Blind Period

    Number of participants positive for anti-drug antibodies (ADAs) to ocrelizumab is the number of post- baseline evaluable participants determined to have treatment-induced ADA or treatment-enhanced ADA during the study period.

    Time frame: Baseline up to Week 96

07

Results

Posted Jul 18, 2017

Participant flow

A total of 1045 participants were screened for entry into the study. Of these, 210 participants failed screening; the main reasons were failure to meet the inclusion/exclusion criteria or unacceptable laboratory values. A total of 835 participants were enrolled in the study.

Participant flow — Overall Study
MilestoneInterferon Beta-1a + Ocrelizumab PlaceboOcrelizumab + Interferon Beta-1a Placebo
Started418417
Entered ole period297350
Completed229225
Not completed189192
Withdrew: Adverse event4042
Withdrew: Death56
Withdrew: Lack of efficacy2210
Withdrew: Lost to follow-up1512
Withdrew: Non-compliance37
Withdrew: Non-compliance with study drug11
Withdrew: Other3033
Withdrew: Physician decision1116
Withdrew: Pregnancy64
Withdrew: Protocol violation12
Withdrew: Study terminated by sponsor32
Withdrew: Withdrawal by subject5154
Withdrew: Missing13

Outcome measures

PrimaryAnnualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks In Double Blind Period

ARR was protocol-defined and calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of exposure to that treatment.

Time frame:
Week 96
Reported as:
Number · relapses/participant year of treatment
Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks In Double Blind Period
relapses/participant year of treatmentInterferon Beta-1a 44 mcg SCOcrelizumab
Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks In Double Blind Period0.290 (0.234 to 0.361)0.155 (0.121 to 0.198)
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · Negative Binomial Model · p = < 0.0001 · Rate ratio: 0.532 · 95% CI 0.397 to 0.714Rate ratio was calculated as Ocrelizumab ARR/Interferon beta-1a 44 mcg SC ARR.
SecondaryTime to Onset of Confirmed Disability Progression (CDP) for at Least 12 Weeks During the Double-Blind Treatment Period

Disability progression was defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) \>=1.0 point from the baseline EDSS score when the baseline score was less than or equal to (\<=) 5.5 B) \>=0.5 point from the baseline EDSS score when the baseline score was \>5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined. Disability progression was considered confirmed when the increase in the EDSS was confirmed at a regularly scheduled visit at least 12 weeks after the initial documentation of neurological worsening. Participants who had initial disability progression with no confirmatory EDSS assessment and who were on treatment at time of clinical cut-off date were censored at the date of their last EDSS assessment.

Time frame:
Week 104
Reported as:
Median · weeks
Time to Onset of Confirmed Disability Progression (CDP) for at Least 12 Weeks During the Double-Blind Treatment Period
weeksInterferon Beta-1a 44 mcg SCOcrelizumab
Time to Onset of Confirmed Disability Progression (CDP) for at Least 12 Weeks During the Double-Blind Treatment PeriodNA (0 to 102)NA (0 to 104)
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · Log Rank · p = = 0.0169 · Hazard ratio (hr): 0.63 · 95% CI 0.42 to 0.92
SecondaryNumber of T1 Gadolinium (Gd)-Enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-Blind Treatment

The total number of T1 gadolinium-enhancing lesions for all participants in the treatment group was calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96.

Time frame:
Baseline up to week 96
Reported as:
Number · lesions
Number of T1 Gadolinium (Gd)-Enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-Blind Treatment
lesionsInterferon Beta-1a 44 mcg SCOcrelizumab
Number of T1 Gadolinium (Gd)-Enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-Blind Treatment46521
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · Negative Binomial Model · p = < 0.0001 · Adjusted rate ratio: 0.051 · 95% CI 0.029 to 0.089Adjusted by baseline T1 Gd lesion (present or not), baseline EDSS (\<4.0 vs. \>=4.0) and geographical region (US vs. rest-of-world). Adjusted rate ratio was calculated as Ocrelizumab adjusted rate/Interferon beta-1a 44 mcg SC adjusted rate.
SecondaryNumber of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double Blind Treatment

The total number of new and/or enlarging T2 lesions for all participants in the treatment group was calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96.

Time frame:
Baseline up to week 96
Reported as:
Number · lesions
Number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double Blind Treatment
lesionsInterferon Beta-1a 44 mcg SCOcrelizumab
Number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double Blind Treatment2103380
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · Negative Binomial Model · p = < 0.0001 · Adjusted rate ratio: 0.171 · 95% CI 0.130 to 0.225Adjusted by baseline T2 lesion count, baseline EDSS (\<4.0 vs. \>=4.0) and geographical region (US vs. rest-of-world). Adjusted rate ratio was calculated as Ocrelizumab adjusted rate/Interferon beta-1a 44 mcg SC adjusted rate.
SecondaryPercentage of Participants With Confirmed Disability Improvement (CDI) for at Least 12 Weeks In Double Blind Period

Disability improvement was assessed only for the subgroup of participants with a baseline EDSS score of \>= 2.0. It was defined as a reduction in EDSS score of: A) \>=1.0 from the baseline EDSS score when the baseline score was \>=2 and \<=5.5 B) \>= 0.5 when the baseline EDSS score \> 5.5. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Confirmed Disability Improvement (CDI) for at Least 12 Weeks In Double Blind Period
percentage of participantsInterferon Beta-1a 44 mcg SCOcrelizumab
Percentage of Participants With Confirmed Disability Improvement (CDI) for at Least 12 Weeks In Double Blind Period18.83 (14.62 to 23.65)21.38 (17.01 to 26.30)
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · CMH Chi-Squared test (stratified) · p = = 0.4019 · Relative risk (stratified): 1.14 · 95% CI 0.84 to 1.56Stratified by Geographical Region (US vs. Rest of World) and baseline EDSS (\<4.0 vs. \>=4.0).
SecondaryTime to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks During the Double-Blind Treatment Period

Disability progression was defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) \>=1.0 point from the baseline EDSS score when the baseline score was less than or equal to (\<=) 5.5 B) \>=0.5 point from the baseline EDSS score when the baseline score was \>5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined. Disability progression was considered confirmed when the increase in the EDSS was confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. Participants who had initial disability progression with no confirmatory EDSS assessment and who were on treatment at time of clinical cut-off date were censored at the date of their last EDSS assessment.

Time frame:
Week 104
Reported as:
Median · weeks
Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks During the Double-Blind Treatment Period
weeksInterferon Beta-1a 44 mcg SCOcrelizumab
Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks During the Double-Blind Treatment PeriodNA (0 to 102)NA (0 to 104)
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · Log Rank · p = = 0.037 · Hazard ratio (hr): 0.63 · 95% CI 0.40 to 0.98
SecondaryNumber of T1 Hypointense Lesions During the Double-Blind Treatment

The total number of new T1-Hypo-Intense Lesions (Chronic Black Holes) for all participants in the treatment group was calculated as the sum of the individual number of new lesions at Weeks 24, 48, and 96.

Time frame:
Baseline up to week 96
Reported as:
Number · lesions
Number of T1 Hypointense Lesions During the Double-Blind Treatment
lesionsInterferon Beta-1a 44 mcg SCOcrelizumab
Number of T1 Hypointense Lesions During the Double-Blind Treatment1484567
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · Negative Binomial Model · p = < 0.0001 · Adjusted rate ratio: 0.357 · 95% CI 0.272 to 0.47Adjusted by baseline T1-hypointense lesion count, baseline EDSS (\<4.0 vs. \>=4.0) and geographical region (US vs. rest-of-world). Adjusted rate ratio was calculated as Ocrelizumab adjusted rate/Interferon beta-1a 44 mcg SC adjusted rate.
SecondaryChange From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score to Week 96 In Double Blind Period

MSFC score consists of: A) Timed 25-Foot walk; B) 9-Hole Peg Test (9-HPT); and C) Paced Auditory Serial Addition Test (PASAT-3 version). The MSFCS is based on the concept that scores for these three dimensions (arm, leg, and cognitive function) are combined to create a single score (the MSFC) that can be used to detect change over time in a group of participants with MS. Since the three primary measures differ in what they actually measure, a common composite score for the three different measures i.e., Z- score was selected for the purpose. MSFC Score = {Z arm, average + Z leg, average + Z cognitive} / 3.0. The results from each of these three tests are transformed into Z-scores and averaged to yield a composite score for each participant at each time point. A score of +1 indicates that, on average, an individual scored 1 standard deviation (SD) better than the reference population and a score of -1 indicates that an individual scored 1 SD worse than the reference population.

Time frame:
Baseline, Week 96
Reported as:
Mean · Z-score
Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score to Week 96 In Double Blind Period
Z-scoreInterferon Beta-1a 44 mcg SCOcrelizumab
Unadjusted Baseline mean (n= 342, 358)-0.001 ± 0.0330.026 ± 0.034
Adjusted Week 96 mean (n= 269, 308)0.169 ± 0.0290.276 ± 0.028
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · mixed-effect model of repeated measures · p = = 0.004 · Difference in adjusted means: 0.107 · 95% CI 0.034 to 0.180Difference in adjusted means was calculated as Ocrelizumab adjusted mean at Week 96/ Interferon beta-1a 44 mcg SC adjusted mean at Week 96.
SecondaryPercent Change in Brain Volume as Detected by Brain Magnetic Resonance Imaging (MRI) From Week 24 to Week 96 In Double Blind Period

Brain volume was recorded as an absolute "normalized" value at the baseline visit then recorded at subsequent visits as a percentage change relative to the absolute value at the baseline visit. Therefore, brain volume at Week 24 was calculated as the brain volume at the baseline visit multiplied by 1 + (\[percentage change in brain volume from baseline visit to Week 24\]/100). Estimates are from analysis based on mixed-effect model of repeated measures (MMRM) using unstructured covariance matrix: Percentage Change = Brain Volume at Week 24 + Geographical Region (US vs. ROW) + Baseline EDSS (\< 4.0 vs. \>= 4.0) + Week + Treatment + Treatment\*Week (repeated values over Week) + Brain Volume at Week 24\*Week. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis).

Time frame:
From week 24 up to week 96
Reported as:
Mean · percent change
Percent Change in Brain Volume as Detected by Brain Magnetic Resonance Imaging (MRI) From Week 24 to Week 96 In Double Blind Period
percent changeInterferon Beta-1a 44 mcg SCOcrelizumab
Percent Change in Brain Volume as Detected by Brain Magnetic Resonance Imaging (MRI) From Week 24 to Week 96 In Double Blind Period-0.75 ± 0.051-0.638 ± 0.049
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · mixed-effect model of repeated measures · p = = 0.09 · Difference in adjusted means: 0.112 · 95% CI -0.018 to 0.241Difference in the rate of brain volume loss: 14.9%. Difference in adjusted means was calculated as Ocrelizumab adjusted mean at Week 96/ Interferon beta-1a 44 mcg SC adjusted mean at Week 96.
SecondaryChange From Baseline in Short Form Health Survey-36 (SF-36) Physical Component Summary (PCS) Score at Week 96 In Double Blind Period

The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t- scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.

Time frame:
Baseline, Week 96
Reported as:
Mean · t-score
Change From Baseline in Short Form Health Survey-36 (SF-36) Physical Component Summary (PCS) Score at Week 96 In Double Blind Period
t-scoreInterferon Beta-1a 44 mcg SCOcrelizumab
Unadjusted Baseline mean (n= 319, 355)44.552 ± 0.54444.307 ± 0.541
Adjusted mean change at week 96(n=276, 315)-0.833 ± 0.4720.326 ± 0.444
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · mixed-effect model of repeated measures · p = = 0.0404 · Difference in adjusted means: 1.159 · 95% CI 0.051 to 2.268Difference in adjusted means was calculated as Ocrelizumab adjusted mean at Week 96/ Interferon beta-1a 44 mcg SC adjusted mean at Week 96.
SecondaryPercentage of Participants Who Have No Evidence of Disease Activity (NEDA) up to Week 96 In Double Blind Period

NEDA was defined only for participants with a baseline EDSS score \>=2.0. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). Participants who completed the 96- week treatment period were considered as having evidence of disease activity if at least one protocol- defined relapse (PDR), a confirmed disability progression (CDP) event or at least one MRI scan showing MRI activity (defined as Gd-enhancing T1 lesions, or new or enlarging T2 lesions) was reported during the 96-week treatment period, otherwise the participant was considered as having NEDA.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants Who Have No Evidence of Disease Activity (NEDA) up to Week 96 In Double Blind Period
percentage of participantsInterferon Beta-1a 44 mcg SCOcrelizumab
Percentage of Participants Who Have No Evidence of Disease Activity (NEDA) up to Week 96 In Double Blind Period24.1 (19.1 to 29.6)43.9 (38.1 to 49.9)
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · CMH Chi-Squared test (stratified) · p = < 0.0001 · Relative risk (stratified): 1.81 · 95% CI 1.41 to 2.32Analyzed using CMH test, stratified by Geographical Region (US vs. rest-of-world) and baseline EDSS (\<4.0 vs. \>=4.0).
SecondaryNumber of Participants With Adverse Events (AEs)

AEs included infusion related reactions (IRRs) and serious MS relapses, but excluded non-serious MS relapses. Serious Adverse Events (SAEs) included serious MS relapses and serious IRRs.

Time frame:
Baseline up to Week 96
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsInterferon Beta-1a + Ocrelizumab Placebo (Double Blind Period)Ocrelizumab + Interferon Beta-1a Placebo (Double Blind Period)Interferon Beta-1a + Placebo (Open Label Extension)Ocrelizumab + Placebo (Open Label Extension)
Adverse Events357360281333
Serious Adverse Events402971121
SecondaryExposure to Ocrelizumab (Area Under the Concentration - Time Curve, AUC) In Double Blind Period

AUC represents total drug exposure for one dosing interval after the 4th dose.

Time frame:
Pre-infusion at Weeks 1, 24, 48, 72; and 30 minutes post-infusion at Week 72; at any time during Weeks 84 and 96
Reported as:
Mean · micrograms per milliter*day
Exposure to Ocrelizumab (Area Under the Concentration - Time Curve, AUC) In Double Blind Period
micrograms per milliter*dayOcrelizumab
Exposure to Ocrelizumab (Area Under the Concentration - Time Curve, AUC) In Double Blind Period3513 ± 955
SecondaryNumber of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab In Double Blind Period

Number of participants positive for anti-drug antibodies (ADAs) to ocrelizumab is the number of post- baseline evaluable participants determined to have treatment-induced ADA or treatment-enhanced ADA during the study period.

Time frame:
Baseline up to Week 96
Reported as:
Number · participants
Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab In Double Blind Period
participantsInterferon Beta-1a 44 mcg SCOcrelizumab
Positive sample at baseline (n= 407, 402)24
Positive for ADA post-baseline (n= 403, 405)52

Adverse events

Collected over Baseline to approximately 588 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Interferon Beta-1a + Ocrelizumab Placebo (Double Blind)1/417 (0.2%)40/417 (9.6%)357/417 (85.6%)
Ocrelizumab + Interferon Beta-1a Placebo (Double Blind)1/417 (0.2%)29/417 (7%)360/417 (86.3%)
Interferon Beta-1a + Ocrelizumab Placebo (Double Blind) Ocrelizumab (Open Label)5/297 (1.7%)71/297 (23.9%)266/297 (89.6%)
Ocrelizumab + Interferon Beta-1a Placebo (Double Blind) Ocrelizumab (Open Label)6/350 (1.7%)121/350 (34.6%)317/350 (90.6%)
Most frequent serious events
Showing 10 of 229
Most frequent serious events
EventInterferon Beta-1a + Ocrelizumab Placebo (Double Blind)Ocrelizumab + Interferon Beta-1a Placebo (Double Blind)Interferon Beta-1a + Ocrelizumab Placebo (Double Blind) Ocrelizumab (Open Label)Ocrelizumab + Interferon Beta-1a Placebo (Double Blind) Ocrelizumab (Open Label)
COVID-19 PNEUMONIAInfections and infestations0/4170/41713/29723/350
PNEUMONIAInfections and infestations2/4171/4176/29715/350
COVID-19Infections and infestations0/4170/4179/29713/350
URINARY TRACT INFECTIONInfections and infestations1/4170/4174/2973/350
PYREXIAGeneral disorders0/4170/4170/2973/350
CHOLECYSTITISHepatobiliary disorders0/4171/4171/2973/350
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders0/4170/4170/2973/350
APPENDICITISInfections and infestations0/4173/4170/2971/350
POSTOPERATIVE WOUND INFECTIONInfections and infestations0/4170/4172/2970/350
BREAST CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4170/4172/2970/350
Most frequent other events
Showing 10 of 44
Most frequent other events
EventInterferon Beta-1a + Ocrelizumab Placebo (Double Blind)Ocrelizumab + Interferon Beta-1a Placebo (Double Blind)Interferon Beta-1a + Ocrelizumab Placebo (Double Blind) Ocrelizumab (Open Label)Ocrelizumab + Interferon Beta-1a Placebo (Double Blind) Ocrelizumab (Open Label)
INFUSION RELATED REACTIONInjury, poisoning and procedural complications50/417158/41797/29763/350
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations53/41765/41786/297107/350
NASOPHARYNGITISInfections and infestations41/41780/41765/29796/350
URINARY TRACT INFECTIONInfections and infestations39/41743/41779/29796/350
COVID-19Infections and infestations0/4170/41766/29796/350
MULTIPLE SCLEROSIS RELAPSENervous system disorders0/4170/41770/29782/350
INFLUENZA LIKE ILLNESSGeneral disorders92/41723/41715/29726/350
HEADACHENervous system disorders71/41760/41749/29768/350
COUGHRespiratory, thoracic and mediastinal disorders0/4170/41726/29758/350
BRONCHITISInfections and infestations13/41722/41725/29757/350

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants in the study.

Age, Continuous
Age, Continuous(years)Interferon Beta-1a + Ocrelizumab Placebo (Double Blind Period)Ocrelizumab + Interferon Beta-1a Placebo (Double Blind Period)Total
Mean37.4 ± 9.037.2 ± 9.137.3 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Interferon Beta-1a + Ocrelizumab Placebo (Double Blind Period)Ocrelizumab + Interferon Beta-1a Placebo (Double Blind Period)Total
Female280271551
Male138146284
08

Study locations

165 sites
  • Hope Research Institute
    Phoenix, Arizona 85050, United States
  • HonorHealth Neurology
    Scottsdale, Arizona 85251, United States
  • Territory Neurology and Research Institute
    Tucson, Arizona 85704, United States
  • Collaborative Neuroscience Research, LLC
    Long Beach, California 90806, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • University of Colorado
    Denver, Colorado 80262, United States
  • Advanced Neurosciences Research LLC
    Fort Collins, Colorado 80528, United States
  • Associated Neurologists of Southern CT PC
    Fairfield, Connecticut 06824, United States
  • Infinity Clinical Research
    Hollywood, Florida 33024, United States
  • University of Miami; Dept. of Neurology MS Center
    Miami, Florida 33136, United States
  • Neurological Services of Orlando
    Orlando, Florida 32806, United States
  • Lovelace Scientific Resources
    Sarasota, Florida 34292, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Atlanta Neuroscience Institute
    Atlanta, Georgia 30327, United States
  • Josephson Wallack Munshower Neurology PC
    Indianapolis, Indiana 46256, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • MidAmerica Neuroscience Institute
    Prairie Village, Kansas 66206, United States
  • Associates in Neurology PSC
    Lexington, Kentucky 40513, United States
  • Dragonfly Research, LLC
    Wellesley, Massachusetts 02481, United States
  • University of Massachusetts Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109-0666, United States
  • Wayne State University; Department of Neurology
    Detroit, Michigan 48201, United States
  • The Minneapolis Clinic of Neurology
    Golden Valley, Minnesota 55422, United States
  • Rutgers New Jersey Medical School
    Newark, New Jersey 07103, United States
  • Holy Name Hospital
    Teaneck, New Jersey 07666, United States
  • MS Comprehensive Care Center
    Teaneck, New Jersey 07666, United States
  • Shore Neurology
    Toms River, New Jersey 08755, United States
  • Empire Neurology, PC
    Latham, New York 12210, United States
  • Weill Cornell MC-NY Presbyter; Dept. of Neurology/Neuroscience, Judith Jaffe Multiple Sclerosis Ctr
    New York, New York 63110, United States
  • South Shore Neurologic Associates P.C.
    Patchogue, New York 11772, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • SUNY at Stony Brook
    Stony Brook, New York 11790, United States
  • The Neurological Institute PA
    Charlotte, North Carolina 28204, United States
  • Neurology Associates PA
    Hickory, North Carolina 28602, United States
  • Raleigh Neurology Associates
    Raleigh, North Carolina 27607-6520, United States
  • Columbus Neuroscience
    Columbus, Ohio 43801, United States
  • Abington Neurological Associates
    Abington, Pennsylvania 19001, United States
  • Absher Neurology PA
    Greenville, South Carolina 29607, United States
  • Neurology Clinic PC
    Cordova, Tennessee 38018, United States
  • Sibyl Wray MD Neurology PC
    Knoxville, Tennessee 37934, United States
  • Advanced Neurosciences Institute
    Nashville, Tennessee 37205, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-0001, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Bhupesh Dihenia M.D. P.A.
    Lubbock, Texas 79410, United States
  • Central Texas Neurology Consultants
    Round Rock, Texas 78681, United States
  • Integra Clinical Research, Llc
    San Antonio, Texas 78229, United States
  • Neurology Center of San Antonio
    San Antonio, Texas 78258, United States
  • Swedish Neuroscience Institute
    Seattle, Washington 98122, United States
  • ALPI-Inst. de Rehabilitacion Marcelo Fitte
    Buenos Aires, C1425BWO, Argentina
  • STAT Research S.A.
    Ciudad de Buenos Airesa, C1013AAB, Argentina
  • Grodno State Medical University
    Grodno, Hrodzyenskaya Voblasts' 230017, Belarus
  • Vitebsk; Regional Diagnostic Center
    Vitebsk, Vitsyebskaya Voblasts' 210023, Belarus
  • Vitebsk Regional Clinical Hospital
    Vitebsk, Vitsyebskaya Voblasts' 210037, Belarus
  • City Clinical Hospital #9
    Minsk, 220116, Belarus
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • University Clinic Ctr Sarajevo
    Sarajevo, 71 000, Bosnia and Herzegovina
  • Uni Hospital Center Tuzla
    Tuzla, 75000, Bosnia and Herzegovina
  • Santa Casa de Misericordia; de Belo Horizonte
    Belo Horizonte, MG 30150-221, Brazil
  • Hospital Universitario Gaffree e Guinle
    Rio de Janeiro, RJ 20270-004, Brazil
  • Hospital das Clinicas - UNICAMP
    Campinas, SP 13083-887, Brazil
  • MHATNP Sv.Naum EAD; Clinic for intensive treatment of neurology diseases
    Sofia, 1113, Bulgaria
  • Fifth MHAT-Sofia AD; Neuro Dept with Vascular Unit
    Sofia, 1233, Bulgaria
  • MHAT National Cardiology Hospital, EAD; Neurology
    Sofia, 1309, Bulgaria
  • UMHAT Alexandrovska, EAD; Neurology
    Sofia, 1431, Bulgaria
  • Multiple Sclerosis Clinic
    Calgary, Alberta T2N 2T9, Canada
  • University of Alberta; Northern Alberta Trials & Research Centre
    Edmonton, Alberta T6G 2C8, Canada
  • Vancouver Hospital - UBC Hospital Site
    Vancouver, British Columbia V6Z 1Y6, Canada
  • The Ottawa Hospital - General Campus
    Ottawa, Ontario K1H 8L6, Canada
  • Clinique NeuroOutaouais
    Gatineau, Quebec J8Y 1W2, Canada
  • Recherche Sepmus Inc.
    Greenfield Park, Quebec J4V 2J2, Canada
  • Montreal Neurological Institute and Hospital
    Montreal, Quebec H3A 2B4, Canada
  • Hôpital Maisonneuve - Rosemont; Recherche Clinique de Neurologie
    Montréal, Quebec H1T 2M4, Canada
  • General Hospital Pula
    Pula, 52100, Croatia
  • General Hospital Varazdin
    Varazdin, 42000, Croatia
  • Clinical Hospital Centre Zagreb;Clinic for Neurology
    Zagreb, 10000, Croatia
  • Uni Hospital Centre Dubrava
    Zagreb, 10000, Croatia
  • Fakultni nemocnice Brno
    Brno, 613 00, Czechia
  • Neurospol s.r.o.
    Havirov, 736 00, Czechia
  • Pardubicka Krajska Nemocnice; Department of Neurology
    Pardubice, 532 03, Czechia
  • Krajska zdravotni, a. s. ? Nemocnice Teplice, o. z.; Neurologicke oddeleni
    Teplice, 415 29, Czechia
  • Hopital Neurologique Pierre Wertheimer
    Bron, 69500, France
  • Hôpital General - Service de neurologie; Service de neurologie
    Dijon Cedex, 21079, France
  • Hôpital Saint Philibert
    Lommé, 59462, France
  • Groupe Hospitalier Pitie-Salpetriere
    Paris, 75651, France
  • Hôpital Maison Blanche; Service de Neurologie
    Reims, 51092, France
  • CHU toulouse - Hôpital Purpan; Departement de Neurologie
    Toulouse, 31059, France
  • Sankt Gertrauden Krankenhaus; Neurologisches Facharztzentrum
    Berlin, 10713, Germany
  • Neurologische Praxis Bonn
    Bonn, 53117, Germany
  • Universitätsklinikum Düsseldorf; Klinik für Neurologie
    Düsseldorf, 40225, Germany
  • Zentrum fuer ambulante Neurologie
    Essen, 45138, Germany
  • Universitaetsklinikum Frankfurt; Klinik für Neurologie
    Frankfurt, 60528, Germany
  • Universitaetsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Ratsapotheke Mittweida
    Mittweida, 09648, Germany
  • Klinikum Grosshadern der LMU
    Muenchen, 81377, Germany
  • Klinikum rechts der Isar der TU Muenchen; Neurologische Klinik und Poliklinik im Neuro-Kopf-Zentrum
    München, 81675, Germany
  • Neurologische Gemeinschaftspraxis Dr. Lang, Prof. Schreiber, Dr. Krauß, Dr. Kornhuber
    Ulm, 89073, Germany
  • St Vincents University Hospital
    Dublin 4, Ireland
  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata
    Roma, Lazio 00133, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, Lazio 00168, Italy
  • A.O. Universitaria S. Martino Di Genova
    Genova, Liguria 16132, Italy

Showing the first 100 of 165 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Arnold DL, Sprenger T, Bar-Or A, Wolinsky JS, Kappos L, Kolind S, Bonati U, Magon S, van Beek J, Koendgen H, Bortolami O, Bernasconi C, Gaetano L, Traboulsee A. Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Mult Scler. 2022 Oct;28(12):1927-1936. doi: 10.1177/13524585221097561. Epub 2022 Jun 7. PubMed 35672926 ↗
  • Krishnan AP, Song Z, Clayton D, Gaetano L, Jia X, de Crespigny A, Bengtsson T, Carano RAD. Joint MRI T1 Unenhancing and Contrast-enhancing Multiple Sclerosis Lesion Segmentation with Deep Learning in OPERA Trials. Radiology. 2022 Mar;302(3):662-673. doi: 10.1148/radiol.211528. Epub 2021 Dec 14. PubMed 34904871 ↗
  • Giovannoni G, Kappos L, de Seze J, Hauser SL, Overell J, Koendgen H, Manfrini M, Wang Q, Wolinsky JS. Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials. Eur J Neurol. 2022 Apr;29(4):1238-1242. doi: 10.1111/ene.14823. Epub 2021 May 5. PubMed 33724637 ↗
  • Hauser SL, Kappos L, Arnold DL, Bar-Or A, Brochet B, Naismith RT, Traboulsee A, Wolinsky JS, Belachew S, Koendgen H, Levesque V, Manfrini M, Model F, Hubeaux S, Mehta L, Montalban X. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020 Sep 29;95(13):e1854-e1867. doi: 10.1212/WNL.0000000000010376. Epub 2020 Jul 20. PubMed 32690791 ↗
  • Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model F, Koendgen H, Manfrini M, Belachew S, Hauser SL. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020 Sep 1;77(9):1132-1140. doi: 10.1001/jamaneurol.2020.1568. PubMed 32511687 ↗
  • Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. PubMed 28002679 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2011 to primary completion in May 2015, 43 months.

Results were first posted in Jul 2017, 2 years 2 months after primary completion. A results delay was requested in Oct 2016.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 43 months is above that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2011
First posted
Aug 9, 2011
StartActual
Sep 20, 2011
Primary completionActual
May 12, 2015
CompletionActual
Dec 30, 2022
Results delay requested
Oct 21, 2016
Results first posted
Jul 18, 2017
Last update
Mar 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01412333
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 9, 2011
Start date
Sep 20, 2011
Primary completion
May 12, 2015
Completion
Dec 30, 2022
Results posted
Jul 18, 2017
Last update
Mar 8, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion